RoundTable Healthcare Partners Invests in Colorescience to Scale Clinically-Backed Mineral Sunscreens and Skincare

Table of Contents

1. Key Highlights:
2. Introduction
3. Colorescience’s proposition: clinical validation meets cosmetic elegance
4. Distribution architecture: an omni-channel model with practitioner roots
5. Why RoundTable: an “operating-oriented” approach tailored to healthcare
6. Market context: sun protection, practitioner brands, and consumer expectations
7. Product science and formulation considerations: mineral filters, nanoparticles, and cosmetic outcomes
8. Deal structure and financing: who’s involved and what it signals
9. Growth levers: product, channel, international expansion, and partnerships
10. Risks and tensions: preserving brand integrity while scaling
11. Regulatory environment and labeling: how sunscreens are judged
12. Practical outcomes for consumers and clinicians
13. Comparisons and precedents: how clinician-led brands have scaled
14. What the investment means for the competitive landscape
15. Execution priorities: where RoundTable will likely focus first
16. Potential timelines and milestones to monitor
17. Real-world examples that illustrate the path forward
18. Strategic considerations for practitioners and industry observers
19. FAQ

Key Highlights:

• RoundTable Healthcare Partners has acquired Colorescience from 1315 Capital, marking the firm's third platform investment from its $800 million Equity Fund VI and its ninth consumer healthcare platform investment.
• Colorescience’s strength lies in mineral-based, clinically validated sun protection and skincare trusted by dermatologists and medical professionals; the partnership aims to expand brand awareness, broaden distribution across professional, direct-to-consumer, and e-commerce channels, and accelerate product innovation.

Introduction

A private-equity investment announced by RoundTable Healthcare Partners in Colorescience signals a coming phase of scale for a brand built on clinician trust and mineral-based formulations. Colorescience has cultivated credibility among dermatologists, plastic surgeons, aestheticians, and medical-spa operators by centering its products on clinical validation and wearability—sunscreens and skincare that protect without sacrificing cosmetic finish.

RoundTable’s operating-oriented approach and healthcare specialization make the partnership meaningful beyond capital: it is intended to provide operational resources, practitioner-channel expertise, and distribution muscle to turn an established clinical brand into a larger consumer-healthcare platform. The deal also reflects larger dynamics: practitioner-recommended brands and scientifically grounded skincare are priorities for investors, and sun protection remains a central, defensible category where product efficacy and professional endorsement carry outsized influence.

Below is an examination of what sets Colorescience apart, how RoundTable frames its playbook, the market and regulatory context that will shape execution, and what the investment could mean for customers, practitioners, and the competitive set in skincare and sun care.

Colorescience’s proposition: clinical validation meets cosmetic elegance

Colorescience’s positioning centers on two attributes that often sit at odds in sun care: proven protection and pleasant daily wear. Mineral sunscreens—typically formulated with zinc oxide and titanium dioxide—provide broad-spectrum ultraviolet protection and are favored in clinical settings for their safety profile and lower irritation potential compared with some chemical filters. Colorescience emphasizes mineral-based formulations that have undergone clinical testing, and it pairs that science-first stance with finishes designed to be cosmetically acceptable for daily use.

This combination creates utility for multiple customer groups:

• Dermatologists and plastic surgeons who recommend products to repair and protect compromised skin after procedures.
• Aestheticians and medical spas seeking post-procedure products that minimize irritation while supporting cosmetic outcomes.
• Consumers who want sun protection that layers under makeup or substitutes for foundation with tint and finish.

Clinician endorsement matters in skincare more than ever. Brands that earn and maintain professional trust benefit from both a steady referral stream and the credibility that convinces discerning consumers to pay a premium. Colorescience has cultivated that credibility through clinical studies, practitioner outreach, and product formats—tinted sunscreens, powder sunscreens, and skincare formulations—that address real clinical and lifestyle needs.

Cosmetic elegance is not a superficial attribute. Routine daily protection depends on user adherence. Sunscreens that leave visible white casts, feel greasy, or interfere with makeup reduce compliance. A clinically validated mineral formula with a cosmetically pleasing finish raises the baseline likelihood that consumers will use it every day, improving public-health outcomes around UV exposure and skin cancer risk.

Distribution architecture: an omni-channel model with practitioner roots

Colorescience sells through a diversified omni-channel model that spans:

• The professional channel: clinics, dermatology offices, plastic surgery practices, medical spas.
• Direct-to-consumer (DTC): brand-owned online storefronts and subscription options.
• Leading e-commerce platforms and retail partners.

Each channel plays a distinct role. The professional channel gives the brand credibility and recurring recommendations from trusted clinicians. DTC allows for higher margins, control over customer experience, and the ability to gather first-party data for marketing and product development. E-commerce platforms extend reach and support discoverability for new customers.

Strategically, the mix of channels both protects and amplifies the brand. Clinician-recommended products are often discovery engines for e-commerce and DTC sales, while DTC also feeds professional demand when consumers request specific brands at appointments. For private equity, an omni-channel brand presents multiple levers to drive growth: expand penetration in existing channels, increase conversion rates in e-commerce, strengthen practitioner partnerships, and invest in new international or retail distribution where profitable.

Examples in the wider market reflect similar trajectories. Many clinician-endorsed brands have scaled by combining professional credibility with DTC analytics and digital patient acquisition—building direct relationships with end consumers without abandoning practitioner recommendations. Execution often hinges on maintaining product integrity while professionalizing marketing and supply-chain operations.

Why RoundTable: an “operating-oriented” approach tailored to healthcare

RoundTable Healthcare Partners positions itself as an operating-oriented private equity investor focused exclusively on healthcare. That focus matters: healthcare and practitioner-oriented consumer brands require different playbooks than mass-market beauty companies. Operational support that understands clinical channels, regulatory nuance, and the referral dynamics of healthcare markets is more likely to add value without eroding brand equity.

RoundTable’s pitch to Colorescience emphasizes:

• Dedicated operating resources and channel expertise, particularly for practitioner-oriented brands.
• Experience building consumer healthcare platforms and partnering with management teams.
• A track record of working with founders, family companies, and clinicians who value stewardship.

This is RoundTable’s third platform investment from Fund VI and is described as its ninth consumer healthcare platform investment overall. The firm has raised multiple funds and positions itself to back companies that combine clinical credibility and consumer appeal.

Private equity execution in consumer healthcare typically focuses on:

• Scaling customer acquisition while preserving the brand’s professional relationships.
• Strengthening supply chain and inventory management to support omni-channel demand spikes.
• Investing in clinical studies and product development to extend the brand’s defensibility.
• Expanding into adjacent categories where the brand’s clinical reputation confers advantages.

RoundTable’s team includes individuals with experience in healthcare operations and commercial strategy, which helps bridge the gap between clinician expectations and consumer-growth imperatives. For Colorescience, that means the potential to scale without losing the clinical trust that defines its market position.

Market context: sun protection, practitioner brands, and consumer expectations

Sun protection is a unique category within skincare. It is both a clinical product—with measurable efficacy metrics such as SPF and broad-spectrum protection—and a daily cosmetic that must satisfy texture, finish, and aesthetic expectations. Consumer demand for efficacious, friendly-to-sensitive-skin solutions has driven interest in mineral sunscreens and formulations validated in clinical settings.

Key dynamics shaping the market:

• Increased consumer awareness of sun damage and skin cancer risk has lifted demand for daily SPF products.
• Professional endorsements from dermatologists and plastic surgeons influence purchase decisions, particularly for post-procedure care.
• Digital channels and e-commerce now play a major role in discovery and repeat purchases, enabling brands with higher price points but clear clinical value to reach consumers directly and at scale.
• Regulatory attention—on sunscreen claims, labeling, and certain chemical filters—has reinforced interest in mineral-based options that enjoy clear safety profiles.

Competitors and adjacent brands in the practitioner-recommended space include well-known names favored by dermatologists and med-spa professionals. These brands have shown that a practitioner-oriented approach can scale commercially when combined with direct consumer strategies and clear differentiation.

Consumers also increasingly demand transparency: ingredient lists, clinical evidence, manufacturing standards, and dermatologist recommendations resonate. Brands that marry evidence with experience—clinical validation paired with pleasant wear—are positioned to capture a disproportionate share of premium buyers.

Product science and formulation considerations: mineral filters, nanoparticles, and cosmetic outcomes

Mineral sunscreens primarily use zinc oxide and titanium dioxide as active filters. They physically block and scatter UV radiation rather than chemically absorbing it. This mechanism offers several practical advantages:

• Lower incidence of irritation and sensitization compared with some chemical filters, making minerals preferable for sensitive and post-procedure skin.
• Immediate efficacy on application, unlike certain chemical filters that require time to bind to the skin.
• A favorable safety profile that reduces regulatory uncertainty for brands.

Formulation challenges with mineral sunscreens have historically included the white cast and poor blendability that come from larger zinc-oxide or titanium-dioxide particles. Advances in formulation science—particle micronization, tinting technology, and hybrid formulations that balance mineral actives with cosmetically elegant bases—overcome these constraints. Colorescience has emphasized cosmetic finishes that enable daily use by consumers and post-procedure patients.

Nanoparticles have been used to reduce visible whiteness while retaining UV protection. Scientific review suggests that properly formulated nanoparticles of zinc oxide or titanium dioxide pose minimal systemic risk because these particles do not readily penetrate intact skin. Regulatory agencies and independent researchers continue to study nanoparticle behavior, and brands must remain transparent and evidence-driven in their communication.

Clinical validation extends beyond particle science. Studies that demonstrate SPF, UVA protection, photostability, and post-procedure outcomes provide practitioners with the confidence to recommend specific products. Brands that maintain ongoing clinical research can preserve practitioner trust even as they scale.

Deal structure and financing: who’s involved and what it signals

RoundTable acquired Colorescience from a group of shareholders led by 1315 Capital. The transaction included senior debt financing provided by Capital One, N.A., as Sole Lead Arranger and Administrative Agent, with participation from CIBC Bank USA and Lord Abbett Private Credit Advisor LLC. Sidley Austin LLP acted as legal counsel to RoundTable; Raymond James served as financial advisor; Greenberg Traurig, LLP served as legal counsel to Colorescience.

These financing details reflect a typical private-equity capitalization where senior debt supports the buyout, and the sponsor brings operational and strategic resources. The presence of established lenders and legal counsel provides a layer of validation for the transaction’s structure and risk assessment.

1315 Capital’s Founding Partner Adele Oliva praised Colorescience’s growth under their stewardship and expressed confidence in RoundTable’s operational focus. Such handoffs between private-equity firms are common when a company has matured past a growth phase that one sponsor managed into a stage where a new partner can amplify scale and market penetration.

RoundTable’s description of Colorescience as its third platform investment from Fund VI signals that the firm deploys concentrated capital into a smaller number of strategic platform investments—aiming to allocate significant resources to a subset of portfolio companies where they believe operational leverage and market dynamics can yield outsized returns.

Growth levers: product, channel, international expansion, and partnerships

Private-equity sponsorship typically unlocks a set of growth levers tailored to a brand’s strengths. For Colorescience, several stands out:

1. Product portfolio expansion
   • Extend beyond core sunscreens into adjunct skincare categories that complement sun protection: post-procedure barrier repair, antioxidant serums, and pigmentation-control formulas.
   • Develop product formats that increase daily adherence: powders, sprays, travel-friendly options, and tinted formulations that double as makeup.
2. Practitioner channel penetration
   • Deepen partnerships with dermatology offices, plastic-surgery clinics, and medical spas through education programs, clinical materials, and practice-focused merchandising.
   • Offer practitioner-exclusive SKUs or packaging that encourages professional recommendations while maintaining consistent product quality.
3. Direct-to-consumer sophistication
   • Invest in customer acquisition strategies—search, social advertising, and influencer partnerships—that foreground clinical credibility and product science rather than only lifestyle appeal.
   • Enhance subscription options, bundling, and personalization to improve retention and lifetime value.
4. E-commerce and retail distribution
   • Expand presence on leading marketplaces and consider selective retail partnerships with specialty beauty or pharmacy chains that curate clinician-recommended products.
   • Carefully manage retail economics to retain margins and brand positioning.
5. International expansion
   • Evaluate regulatory pathways and local sunscreen norms. Some markets have different approved filters and labeling requirements.
   • Prioritize regions with strong dermatology networks and high consumer willingness to pay for clinician-endorsed skincare.
6. Clinical and scientific investment
   • Continue or expand clinical studies demonstrating efficacy for post-procedure recovery, pigmentation improvement, or photoprotection under real-world conditions.
   • Publish data in peer-reviewed venues when appropriate to maintain and enhance professional credibility.

Private equity can accelerate each lever through capital for marketing and R&D, operational expertise in manufacturing and supply chain scaling, and introductions to distribution partners and strategic acquirers.

Risks and tensions: preserving brand integrity while scaling

Scaling a clinician-endorsed brand introduces tensions. High-level risks include:

• Erosion of clinical trust: aggressive direct-marketing tactics, price promotions, or changes in formulation can prompt clinicians to withdraw recommendations. Maintaining product integrity and transparent communication is essential.
• Regulatory scrutiny: sunscreen claims and ingredient safety are under rigorous review by regulators in multiple jurisdictions. Compliance with labeling, testing, and claims substantiation requires investment in regulatory affairs.
• Competitive responses: larger beauty and sun-care brands may respond with new product innovations, pricing pressure, or expanded clinician outreach.
• Supply-chain constraints: ingredient availability (e.g., for mineral actives), packaging sourcing, and production capacity can hamper rapid expansion if not anticipated and managed.
• Channel conflicts: expanding retail distribution and DTC can create friction with practitioner channels that expect preferential terms or exclusivity. Carefully calibrated channel strategies preserve practitioner relationships while growing consumer reach.

Preserving the brand’s clinical soul requires governance: clear product stewardship policies, continued clinical research investment, and marketing that emphasizes evidence over lifestyle claims. Practitioners respond to consistency and scientific transparency; private capital must adopt a long-term mindset to protect those equities.

Regulatory environment and labeling: how sunscreens are judged

Sunscreen regulation varies by jurisdiction, but certain principles are constant: efficacy, safety, and truthful labeling. In the United States, the Food and Drug Administration (FDA) regulates suntan products as over-the-counter drugs and evaluates active ingredients, testing, and labeling claims. Recent years have seen heightened scrutiny on certain chemical filters and demands for better data on long-term safety.

Mineral sunscreens benefit from a clearer regulatory pathway because zinc oxide and titanium dioxide have long-established safety records. Yet mineral brands must still substantiate SPF and broad-spectrum claims, demonstrate photostability, and comply with labeling requirements regarding water resistance and directions for use.

Globally, different countries maintain different permitted active ingredients and testing protocols. Brands aiming for international expansion must invest in local regulatory strategies and product variants if certain filters or claims are not permitted.

Transparency in marketing and the availability of substantiating clinical evidence strengthen a brand’s regulatory standing and practitioner trust. Brands that publicly share summaries of clinical results or that publish peer-reviewed studies tend to enjoy greater professional endorsement.

Practical outcomes for consumers and clinicians

For consumers, the partnership could yield faster innovation cycles, expanded product availability, and potential improvements to customer experience—better DTC platforms, more subscription options, and broader e-commerce reach. Importantly, consumers should expect the core product attributes that built Colorescience’s reputation—mineral-based protection and cosmetically elegant finishes—to be preserved if the partnership executes on its stated commitments.

Clinicians stand to benefit from sustained or enhanced access to clinically validated products for patient recommendations. Investments in clinical research, education, and practice-oriented packaging can make it easier for practitioners to integrate Colorescience into post-procedure protocols and everyday patient advice.

Potential consumer benefits to watch for:

• Wider availability in retail and online channels.
• New product introductions targeting complementary concerns (hyperpigmentation, barrier repair).
• Improved customer service and digital tools for product selection and regimen guidance.

Potential clinician-facing enhancements:

• Continuing medical education (CME)-style programs or practice-focused training materials.
• Samples and starter kits tailored for in-office patient education.
• Data and case studies that help clinicians recommend products to diverse patient populations.

Comparisons and precedents: how clinician-led brands have scaled

While Colorescience’s path is unique, other clinician-endorsed brands demonstrate common scaling patterns. Successful transitions typically retain clinical advocacy while professionalizing operations: adding analytics-driven marketing, fortifying supply chains, and expanding product lines without deviating from core science-based claims.

Some brands have pursued collaborations with dermatologist networks, funded clinical trials that are widely cited, and launched practitioner-only SKUs to maintain professional differentiation. Others have used subscription models and personalized regimens to build loyal consumer bases that offset the impact of promotional retail environments.

Private equity has played a large role in consolidating practitioner-oriented brands when sponsors commit to preserving clinical credibility. Deal success often correlates with clarity about which parts of the business must remain clinician-facing and which can be consumerized. Brands that confuse those lines—diluting clinical messaging in favor of mass-market appeal—risk losing the source of their initial differentiation.

What the investment means for the competitive landscape

RoundTable’s investment underscores investor appetite for consumer-healthcare brands that blend clinical credibility and commercial scalability. For competitors, the signal is clear: practitioners and premium consumers remain a sought-after audience, and brands that can credibly serve them command investor interest.

Competitors may respond by:

• Doubling down on clinical research and practitioner outreach.
• Introducing new mineral-based or hybrid formulations to capture consumers seeking safety and efficacy.
• Investing in DTC capabilities and patient education to deepen direct relationships.

The investment could also prompt consolidation, where other sponsors seek to assemble portfolios of clinician-oriented brands under an operating platform that shares manufacturing, regulatory, and commercial resources. For practitioners, choices will broaden, but their role as gatekeepers and influencers will remain central to brand success.

Execution priorities: where RoundTable will likely focus first

Given RoundTable’s operating-oriented profile and the statements accompanying the deal, immediate execution priorities will likely include:

• Strengthening professional and DTC marketing while safeguarding practitioner relationships.
• Investing in clinical research and evidence generation to deepen differentiation.
• Optimizing supply chain, manufacturing, and inventory capabilities to support omni-channel growth.
• Evaluating international expansion opportunities and regulatory pathways.
• Enhancing digital commerce and customer-retention strategies to maximize lifetime value.

Operational improvements that drive predictable revenue growth—subscription adoption, repurchase rates, and practitioner penetration metrics—are central to private-equity success when backing consumer-healthcare companies. The pace and sequencing of investments will reflect a balance between preserving brand equity and unlocking commercial scale.

Potential timelines and milestones to monitor

Key milestones that will indicate progress under new ownership include:

• Announcement of new clinical studies or peer-reviewed publications.
• Expanded retail or marketplace listings, especially in major pharmacy or beauty channels.
• Introduction of new SKUs that align with medical needs (post-procedure recovery, pigmentation therapy).
• Reports of improved DTC metrics: higher conversion, increased subscription uptake, and customer lifetime value.
• International launches in markets with logical regulatory fit.

Investors, practitioners, and competitors will watch for how RoundTable communicates changes: transparency about formulation integrity, continuity of practitioner programs, and visible investments in clinical validation will signal a respectful scale plan that balances commercial ambition with professional stewardship.

Real-world examples that illustrate the path forward

Examples from adjacent brands help clarify plausible scenarios:

• A clinician-recommended sunscreen brand invests in a major clinical trial demonstrating superior post-procedure recovery outcomes and uses the results to drive adoption among plastic surgeons. The trial also becomes a marketing cornerstone that improves consumer trust and conversion on DTC channels.
• A med-spa-focused skincare line that remained niche partners with a private-equity sponsor to professionalize supply chain, reduce out-of-stocks, and launch an international expansion into markets where practitioner endorsement is highly valued. Growth is achieved through joint marketing with practitioner networks and a subscription model for aftercare regimens.
• A dermatology-trusted brand expands into hybrid formulations—blending mineral actives with cosmetic tints and antioxidant serums—and introduces travel- and makeup-friendly formats that broaden daily use occasions. This lowers friction for consumers and raises repeat purchase rates.

Each pathway requires careful management of clinical messages and product consistency. Brands that maintain rigorous scientific support while improving commercial operations capture both practitioner loyalty and consumer scale.

Strategic considerations for practitioners and industry observers

For dermatologists, plastic surgeons, and aesthetic practices, the partnership suggests greater availability and potentially more robust practice-support offerings. Clinicians should evaluate any new product introductions or packaging changes against clinical evidence and patient outcomes, rather than being swayed by marketing alone.

For industry observers and competitors, the transaction reinforces several strategic tenets:

• Clinical validation remains a powerful moat in premium skincare.
• Omni-channel strategies that blend practitioner endorsement with DTC growth offer scalable revenue streams.
• Private-equity capital directed at healthcare-focused consumer brands tends to prioritize long-term value creation through operational improvements, not only short-term marketing plays.

Practices that integrate these clinician-facing brands into standard-of-care protocols should evaluate sample programs, training materials, and evidence dossiers that sponsors and brands make available post-transaction.

FAQ

Q: Who now owns Colorescience? A: Colorescience was acquired by RoundTable Healthcare Partners from a group of shareholders led by 1315 Capital. The transaction details were not disclosed publicly.

Q: What does RoundTable bring beyond capital? A: RoundTable emphasizes an operating-oriented model, bringing dedicated resources for channel expertise, commercial strategy, regulatory navigation, and operational scale. The firm focuses exclusively on healthcare companies, which aligns with Colorescience’s practitioner-led positioning.

Q: Will Colorescience’s formulas or product identity change? A: The company and RoundTable stress a commitment to maintaining the brand’s clinical heritage and trust among practitioners. Any changes to formulations or product positioning would likely be approached cautiously, given the brand’s reliance on clinical credibility and practitioner recommendations.

Q: How does Colorescience differ from mass-market sunscreen brands? A: Colorescience emphasizes mineral-based, clinically validated products with cosmetically elegant finishes trusted by dermatologists and medical spas. The focus on practitioner endorsement and clinical substantiation differentiates it from many mass-market sunscreen brands that compete more on price and mass distribution.

Q: What growth opportunities does RoundTable see? A: Opportunities include expanding brand awareness across channels, accelerating penetration in DTC and e-commerce, deepening practitioner-channel relationships, broadening the product portfolio, and potentially pursuing international expansion.

Q: Are there regulatory issues to watch for with mineral sunscreens? A: Mineral actives like zinc oxide and titanium dioxide have long safety records. However, sunscreen regulation is complex and evolving. Brands must substantiate claims, comply with labeling requirements, and be responsive to regional regulatory differences, especially when scaling internationally.

Q: How might this partnership affect prices for consumers? A: Transaction-related investments in R&D, clinical studies, and channel expansion do not automatically translate to price increases. Brands often balance investment with competitive pricing, promotions, and subscription models. Any pricing changes will likely reflect market positioning, cost structure, and strategic priorities.

Q: Will practitioner-only products continue to exist? A: Practitioner-only SKUs are often part of the product mix for clinician-recommended brands. Preserving these offerings can be a strategic priority to maintain professional differentiation; however, specifics will depend on RoundTable’s channel strategy and Colorescience’s management decisions.

Q: What should practitioners expect from their suppliers after the deal? A: Practitioners may see enhanced support materials, educational resources, and potentially improved supply reliability. The sponsor’s operating focus commonly includes investments in practice support to reinforce loyal recommendations.

Q: How can consumers verify the clinical claims behind products? A: Consumers should look for published study summaries, third-party testing results, and clear labelling that explains SPF, broad-spectrum protection, and any claims about post-procedure use. Clinician recommendations and reputable sources can also help confirm product credibility.

Q: What milestones will indicate the partnership is working? A: Indicators include sustained or improved practitioner endorsements, higher repurchase and retention rates in DTC channels, successful new product launches with demonstrable clinical support, expanded availability on trusted retail or e-commerce platforms, and financial performance improvements that reflect operational enhancements.

Q: Could this deal lead to consolidation in the clinician-recommended skincare category? A: Private-equity activity often catalyzes consolidation. Brands with strong clinical reputations are attractive targets for sponsors seeking to build scale in consumer healthcare. Market consolidation could accelerate as firms aim to assemble complementary portfolios with operational synergies.

Colorescience’s alignment of clinical rigor and cosmetic acceptability has created a defensible brand that resonates across practitioner and consumer audiences. RoundTable’s investment aims to harness that foundation and apply operational muscle to broaden impact. Execution will rest on preserving the trust that defines the brand while professionalizing commercial, regulatory, and manufacturing capabilities to support sustained growth.